ASX RELEASE 3 September 2026 Paradigm Biopharma Melbourne Investor Lunch Briefing Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), a late-stage drug development company...
Melbourne Investor Lunch
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Appendix 4E and 2026 Annual Report
- Appendix 4G and Corporate Governance Statement
- Application for quotation of securities - PAR
- 80% Safety Review Complete, September IA on Track
- June 2026 Quarterly Activities Report & Appendix 4C
Later from Paradigm Biopharmaceuticals
- Drawdown of Tranche 4 under the Convertible Note Facility
- Notification regarding unquoted securities - PAR
- Notice under Section 708A
- Dr Daniel Furtner appointed Chief Medical Officer
- Trading Halt
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals